154 related articles for article (PubMed ID: 11382369)
1. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication.
Hiatt WR; Regensteiner JG; Creager MA; Hirsch AT; Cooke JP; Olin JW; Gorbunov GN; Isner J; Lukjanov YV; Tsitsiashvili MS; Zabelskaya TF; Amato A
Am J Med; 2001 Jun; 110(8):616-22. PubMed ID: 11382369
[TBL] [Abstract][Full Text] [Related]
2. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study.
Brevetti G; Perna S; Sabbá C; Martone VD; Condorelli M
J Am Coll Cardiol; 1995 Nov; 26(6):1411-6. PubMed ID: 7594063
[TBL] [Abstract][Full Text] [Related]
3. European multicenter study on propionyl-L-carnitine in intermittent claudication.
Brevetti G; Diehm C; Lambert D
J Am Coll Cardiol; 1999 Nov; 34(5):1618-24. PubMed ID: 10551714
[TBL] [Abstract][Full Text] [Related]
4. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
[TBL] [Abstract][Full Text] [Related]
5. Effect of propionyl-L-carnitine on quality of life in intermittent claudication.
Brevetti G; Perna S; Sabba C; Martone VD; Di Iorio A; Barletta G
Am J Cardiol; 1997 Mar; 79(6):777-80. PubMed ID: 9070558
[TBL] [Abstract][Full Text] [Related]
6. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease.
Barker GA; Green S; Askew CD; Green AA; Walker PJ
Med Sci Sports Exerc; 2001 Sep; 33(9):1415-22. PubMed ID: 11528327
[TBL] [Abstract][Full Text] [Related]
7. Carnitine and peripheral arterial disease.
Hiatt WR
Ann N Y Acad Sci; 2004 Nov; 1033():92-8. PubMed ID: 15591006
[TBL] [Abstract][Full Text] [Related]
8. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.
Brass EP; Koster D; Hiatt WR; Amato A
Vasc Med; 2013 Feb; 18(1):3-12. PubMed ID: 23321261
[TBL] [Abstract][Full Text] [Related]
10. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.
Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD
Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982
[TBL] [Abstract][Full Text] [Related]
11. Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication.
Strano A
Clin Drug Investig; 2002 Nov; 22(Suppl 1):1-6. PubMed ID: 23315429
[TBL] [Abstract][Full Text] [Related]
12. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease.
Hiatt WR; Creager MA; Amato A; Brass EP
J Cardiopulm Rehabil Prev; 2011; 31(2):125-32. PubMed ID: 20861750
[TBL] [Abstract][Full Text] [Related]
13. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
[TBL] [Abstract][Full Text] [Related]
14. Propionyl-L-carnitine.
Wiseman LR; Brogden RN
Drugs Aging; 1998 Mar; 12(3):243-8; discussion 249-50. PubMed ID: 9534023
[TBL] [Abstract][Full Text] [Related]
15. Propionyl-L-carnitine for intermittent claudication.
Deckert J
J Fam Pract; 1997 Jun; 44(6):533-4. PubMed ID: 9191622
[No Abstract] [Full Text] [Related]
16. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Goldenberg NA; Krantz MJ; Hiatt WR
Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
[TBL] [Abstract][Full Text] [Related]
17. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
Kurklinsky AK; Levy M
Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
[TBL] [Abstract][Full Text] [Related]
18. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
Poole J; Mavromatis K; Binongo JN; Khan A; Li Q; Khayata M; Rocco E; Topel M; Zhang X; Brown C; Corriere MA; Murrow J; Sher S; Clement S; Ashraf K; Rashed A; Kabbany T; Neuman R; Morris A; Ali A; Hayek S; Oshinski J; Yoon YS; Waller EK; Quyyumi AA
JAMA; 2013 Dec; 310(24):2631-9. PubMed ID: 24247554
[TBL] [Abstract][Full Text] [Related]
19. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response.
Hiatt WR; Wolfel EE; Meier RH; Regensteiner JG
Circulation; 1994 Oct; 90(4):1866-74. PubMed ID: 7923674
[TBL] [Abstract][Full Text] [Related]
20. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.
Ahimastos AA; Walker PJ; Askew C; Leicht A; Pappas E; Blombery P; Reid CM; Golledge J; Kingwell BA
JAMA; 2013 Feb; 309(5):453-60. PubMed ID: 23385271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
